Bausch + Lomb Acquires AcuFocus
Thursday, January 26 2023 | 15 h 07 min | News
Bausch + Lomb and AcuFocus, a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.
AcuFocus has delivered breakthrough small aperture intraocular technology to address the diverse unmet needs in eye care, including the IC-8® Apthera™ intraocular lens (IOL), which was approved by the U.S. Food and Drug Administration in July 2022 as the first and only small aperture non-toric extended depth of focus (EDOF) IOL for certain cataract patients who have as much as 1.5 diopters of corneal astigmatism and wish to address presbyopia at the same time.
“Cataracts are the largest contributor to global blindness in adults aged 50 years and older, with more than 15 million individuals, or approximately 45% of the more than 33 million cases of global blindness. We believe that the IC-8 Apthera EDOF IOL will bolster our surgical portfolio by enhancing our IOL offerings, which is a strategic area of focus for Bausch + Lomb,” said Joseph C. Papa, CEO, Bausch + Lomb.
“Bausch + Lomb is a legacy name in eye care with a fully integrated portfolio of offerings in eye health,” said Al Waterhouse, president and CEO, AcuFocus. “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”
Click HERE for the full press release.
